News From SDEE Members

Explora BioLabs will be opening its new preclinical contract research headquarters and fourth vivarium incubator facility in the Coast 9 complex in Sorrento Valley in mid-September. Together with its three other facilities in Torrey Pines Mesa and Mission Bay, Explora will now operate 40,000 square feet of small animal research...

ACD will soon be releasing our 100th cell-based protein tyrosine kinase assay and we invite you to share in the celebration! Our assay platform reveals kinase biologies that can go undetected using more traditional biochemical assays. We want you to learn more about our system and invite you to participate in...

July 1, 2015. Orphagen Pharmaceuticals announced today that the National Institutes of Health (NIH) National Cancer Institute (NCI) has awarded the company $224,954 under the Small Business Innovative Research (SBIR) program to identify small molecule antagonist ligands for an novel drug discovery target for cancer immunotherapy. Orphagen proposes to find...

DUBLIN, Ohio – June 30, 2015 – Cardinal Health Specialty Solutions has been selected to provide regulatory support to the National Center for Advancing Translational Sciences (NCATS) for its Therapeutics for Rare and Neglected Diseases (TRND) program under a research subcontract with Leidos Biomedical Research, Inc. (Leidos Biomed). NCATS is...

Molecular Diagnostics Consulting (MDxC) signed a Mutual Referral Agreement with Business Development Connections (BDC, Greenbrae, CA). MDxC specializes in providing diagnostic R&D guidance to start-up biotech, medical device, digital health and pharmaceutical companies developing FDA, LDT and RUO products. BDC provides business development support in the life sciences industry to contract research organizations...

Collaborative Drug Discovery received a $1.5M Phase 2 SBIR grant to develop their Bioassay Ontology Annotator software. A prototype of this software was successfully developed by CDD using a previously awarded Phase I SBIR grant. The Bioassay Ontology Annotator, a tool to quickly annotate bioassay data, will be the foundation for...

One World Lab entered an agreement with OriGene Technologies, Inc to become a global distributor of OriGene's antibody portfolio. "The addition of OriGene’s proprietary antibodies supports our strategy and broadens our portfolio to more than 75,000 unique antibodies.  Researchers will have several thousand more antibodies to affordably sample, while knowing with confidence that each antibody is...

SDEE member Crinetics Pharmaceuticals  was awarded a $2.7MM fast-track Phase I SBIR grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) to develop somatostatin receptor agonist drugs targeting chronic pain.  

On March 24, 2015 Allele Biotechnology & Pharmaceuticals, Inc. announced Ocata Therapeutics, Inc. will license Allele's induced pluripotent stem cell technology for use in its regenerative ophthalmology products.

Crinetics Pharmaceuticals receives a $1.5MM Phase II SBIR grant to develop orally-available, small molecule kisspeptin receptor antagonists to treat polycystic ovary syndrome (PCOS) and other women’s health disorders.